Development of 3D Cancer Models in Microengineered Systems

A special issue of Micromachines (ISSN 2072-666X). This special issue belongs to the section "B:Biology and Biomedicine".

Deadline for manuscript submissions: closed (31 October 2025) | Viewed by 706

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy
Interests: bone cancers; microfluidics; cancer microenvironment; bone metabolism; osteoporosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to extend an invitation to you to submit your work for the upcoming Micromachines Special Issue entitled "Development of 3D Cancer Models in Microengineered Systems". This Special Issue focuses on utilising microfluidics, lab-on-a-chip technologies, MEMS-based systems, and miniaturised engineering approaches to create 3D cancer models.

The Special Issue aims to showcase groundbreaking advancements in designing, applying, and clinically translating 3D miniaturised models that accurately replicate the structural and functional complexity of tumour ecosystems. These models play a crucial role in bridging the gap between in vitro systems and in vivo physiology, providing unparalleled insights into cancer progression, metastasis, and therapeutic resistance, thus reducing the reliance on animal models.

We welcome original research articles, reviews, and methodological papers on 3D model innovations. Submissions may include bioengineered systems such as bioprinted tissues, microfluidic platforms, organ-on-a-chip technologies, or MEMS-based models, potentially incorporating patient-derived organoids and tumour spheroids. These platforms enable the study of stromal tumour crosstalk, extracellular matrix (ECM) remodelling, the formation and impact of nutrient or metabolite gradients, including adaptations driven by hypoxia, as well as mechanical and physical barriers to the infiltration of tumour or immune cells. Such systems can be used for high-throughput drug screening, personalised medicine platforms, testing immunotherapy efficacy, and investigating mechanisms of therapy resistance.

We are also interested in receiving submissions on novel biomaterials and biofabrication strategies that mimic tissue-specific mechanical and biochemical cues. Additionally, we encourage innovations that combine imaging approaches with automated high-throughput platforms for scalable drug testing and phenotypic analysis.

This Special Issue aims to facilitate interdisciplinary exchanges among biologists, engineers, and clinicians to expedite the development of physiologically relevant models. Contributions will highlight innovative approaches to replicate tumour heterogeneity, metastatic niches, and dynamic microenvironmental interactions, thereby advancing the study of tumours, precision oncology, and therapeutic discovery.

By submitting your work, you will be contributing to a collective endeavour to redefine cancer research paradigms through state-of-the-art 3D modelling technologies.

You may choose our Joint Special Issue in Micro.

Dr. Sofia Avnet
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Micromachines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2100 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • three-dimensional cancer models
  • microfluidics and lab-on-a-chip
  • tumour microenvironment and metastasis
  • drug screening and immunotherapy
  • biofabrication and novel biomaterials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 1571 KB  
Review
From Spheroids to Tumor-on-a-Chip for Cancer Modeling and Therapeutic Testing
by Maria Veronica Lipreri, Marilina Tamara Totaro, Nicola Baldini and Sofia Avnet
Micromachines 2025, 16(12), 1343; https://doi.org/10.3390/mi16121343 - 27 Nov 2025
Viewed by 504
Abstract
The high failure rate of anticancer drugs in clinical trials highlights the need for preclinical models that accurately reproduce the structural, biochemical, and mechanical complexity of human tumors. Conventional two-dimensional cultures and animal models often lack the physiological complexity required to predict clinical [...] Read more.
The high failure rate of anticancer drugs in clinical trials highlights the need for preclinical models that accurately reproduce the structural, biochemical, and mechanical complexity of human tumors. Conventional two-dimensional cultures and animal models often lack the physiological complexity required to predict clinical outcomes, driving the development of three-dimensional systems that better emulate the tumor microenvironment. Among these, microfluidic-based spheroid models have emerged as powerful tools for cancer research and drug screening. By integrating 3D spheroids with microfluidics, these platforms allow precise control of nutrient flow, oxygen gradients, shear stress, and interstitial pressure, while supporting co-culture with stromal, immune, and endothelial cells. Such systems enable the investigation of drug response, angiogenesis, metastasis, and immune interactions under dynamic and physiologically relevant conditions. This review summarizes recent advances in microfluidic spheroid models for cancer, covering both carcinomas and sarcomas, with an emphasis on device design, biomaterial integration, and translational validation. Key challenges remain, including technical complexity, scalability constraints, and the absence of standardized protocols. Overall, the merger of microfluidic technology with 3D spheroid culture provides a promising pathway toward predictive, ethical, and personalized preclinical testing, bridging the gap between in vitro modeling and clinical oncology. Full article
(This article belongs to the Special Issue Development of 3D Cancer Models in Microengineered Systems)
Show Figures

Figure 1

Back to TopTop